Home > Resources > Infographics > Focus for Higher Returns in Biopharma

Focus for Higher Returns in Biopharma

Why do the largest biopharma companies struggle to deliver above-average shareholder returns? The short answer: complex, wide-ranging portfolios that undermine focus. According to Bain research, the biggest value creators in biopharma are category leaders. But even category leaders can spread their resources too thin. Companies that combine category leadership with portfolio focus create a powerful multiplier effect and significantly outperform their competitors.

Spotlight

Astir Australia

Astir is Australia's fastest growing brand in high quality Physiotherapy and Allied Health products. We partner with leading global players in the production of Rehabilitation and Physiotherapy products, to wholesale direct to Australia's Allied Health Professionals. With thanks to our passionate and enthusiastic customers, staff and suppliers, Astir has sold over 1 million products since 2011. Over 70% of these to repeat customers.

Other Infographics

What is Adoptive Cell Therapy?

Infographic | February 5, 2020

A type of immunotherapy in which T cells are given to a patient to help the body fight diseases. In cancer therapy, T cells are usually taken from the patient’s own blood or tumor tissue, grown in large numbers in the laboratory, and then given back to the patient to help the immune system fight the cancer.

2021 global life sciences outlook

Infographic | August 24, 2021

The life sciences sector has played a pivotal role amid the COVID-19 pandemic. To cope with the global crisis, traditional competitors partnered to accelerate research and develop the fastest novel vaccine in the history. Governments, health systems, payers, retail pharmacies, and nonprofits are now working collaboratively with the sector to provide widespread distribution and administration.

COVID-19 Summary as of March 13, 2020

Infographic | April 6, 2020

Biomedtracker and Trialtrove have a total of 307 clinical trials for the treatment of COVID-19. 152 initiated trials for the treatment of COVID-19. 155 Trials have been announced but have not yet begun recruitment.

Smart Pharmacovigilance

Infographic | May 23, 2021

Pharmacovigilance (PV) is essential to all life science organizations, ensuring that patients' health comes first. Various trends in global healthcare have transformed today’s PV function into a corporate asset that enhances brand value and contributes to new growth opportunities. However, existing safety systems impose a significant cost burden to operate.

Cancer Drugs Bring in Most Pharma Revenue

Infographic | February 25, 2020

Worldwide cancer drug sales are already way ahead of those of other drugs and the revenue generated by them is expected to grow even larger by 2024. This is according to a report recently released by consultancy Evaluate, which analyses trends in the pharmaceutical sector. According to Evaluate's calculations, oncology drugs reached US$123.8 billion in sales in 2018, more than double that of the next item on the list, drugs treating diabetes with US$48.5 billion dollars in sales. By 2024, cancer drug sales are expected to almost double to US$236.6 billion dollars.

More Infographics

Focus for Higher Returns in Biopharma